Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†

Abuse of opioid analgesics for their psychoactive effects is associated with a large number of fatalities. The effect of making opioid tablets harder to crush/dissolve on opioid‐related fatalities has not been assessed. The objective of this study was to assess the impact of introducing extended‐release oxycodone (ERO [OxyContin®]) tablets containing physicochemical barriers to crushing/dissolving (reformulated ERO) on deaths reported to the manufacturer.

• Publication year

  2014

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2014-06-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.3658PMID 24916486PMCID 4282788
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.

  2014cited by this paper
• Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential

  2013cited by this paper
• Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin® Tablets Compared with Original OxyContin® Tablets in Healthy Adults

  2013cited by this paper
• Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics

  2013cited by this paper
• Evidence-based guidelines on the use of opioids in chronic non-cancer pain--a consensus statement by the Pain Association of Singapore Task Force.

  2013cited by this paper
• Update on tamper-resistant drug formulations.

  2013cited by this paper
• An iterative model for in vitro laboratory assessment of tamper deterrent formulations.

  2013cited by this paper
• Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.

  2013cited by this paper
• Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.

  2013cited by this paper
• Pharmaceutical overdose deaths, United States, 2010.

  2013cited by this paper
• Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida.

  2013cited by this paper
• Community-based opioid overdose prevention programs providing naloxone - United States, 2010.

  2012cited by this paper
• A review of abuse-deterrent opioids for chronic nonmalignant pain.

  2012cited by this paper
• Effect of abuse-deterrent formulation of OxyContin.

  2012cited by this paper
• CDC Grand Rounds: Prescription Drug Overdoes - A U.S. Epidemic

  2012cited by this paper
• Do prescription monitoring programs impact state trends in opioid abuse/misuse?

  2012cited by this paper
• Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year.

  2012cited by this paper
• Prescription drug abuse and DEA-sanctioned drug take-back events: characteristics and outcomes in rural Appalachia.

  2012cited by this paper
• CDC grand rounds: prescription drug overdoses - a U.S. epidemic.

  2012cited by this paper
• Tampering with Prescription Opioids: Nature and Extent of the Problem, Health Consequences, and Solutions

  2011cited by this paper
• Project Lazarus: community-based overdose prevention in rural North Carolina.

  2011cited by this paper
• Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population.

  2011cited by this paper
• Prescription drug monitoring programs and death rates from drug overdose.

  2011cited by this paper
• Abuse risks and routes of administration of different prescription opioid compounds and formulations

  2011cited by this paper
• Post-approval drug safety surveillance.

  2010cited by this paper
• A flood of opioids, a rising tide of deaths.

  2010cited by this paper
• Opioid Formulations Designed to Resist/Deter Abuse

  2010cited by this paper
• Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns, and functional severity.

  2010cited by this paper
• Pharmacological management of persistent pain in older persons.

  2009cited by this paper
• Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

  2009cited by this paper
• Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone

  2009cited by this paper
• Pharmacological Management of Persistent Pain in Older Persons

  2009cited by this paper
• Internet-based Survey of Nonmedical Prescription Opioid Use in the United States

  2008cited by this paper
• Comparisons and Applications of Quantitative Signal Detections for Adverse Drug Reactions (ADRs): An Empirical Study Based On The Food And Drug Administration (FDA) Adverse Event Reporting System (AERS) And A Large Medical Claims Database

  2008cited by this paper
• National addictions vigilance intervention and prevention program (NAVIPPRO™): a real‐time, product‐specific, public health surveillance system for monitoring prescription drug abuse

  2008cited by this paper
• Adverse drug event monitoring at the food and drug administration

  2007cited by this paper
• Psychiatrie and Pain Characteristics of Prescription Drug Abusers Entering Drug Rehabilitation

  2006cited by this paper
• Prescription drug monitoring programs.

  2006cited by this paper
• Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001: A Societal Perspective

  2006cited by this paper
• Direct Costs of Opioid Abuse in an Insured Population in the United States

  2005cited by this paper
• A Profile of OxyContin Addiction

  2004cited by this paper
• Adverse drug event monitoring at the food and drug administration

  2003cited by this paper
• Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases.

  2003cited by this paper
• Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky.

  2003cited by this paper
• The role of databases in drug postmarketing surveillance

  2001cited by this paper
• Dose‐Response and Trend Analysis in Epidemiology: Alternatives to Categorical Analysis

  1995cited by this paper
• Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.

  1994cited by this paper
• Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.

  1993cited by this paper
• Modern Epidemiology 3rd edition

  1986cited by this paper
• [Modern epidemiology].

  1971cited by this paper
• Causality : Models , Reasoning , and Inference

  year unknowncited by this paper

• Executive summary of the guideline for prescribing opioid analgesics for chronic non-cancer pain (third edition) by the Japan Society of Pain Clinicians

  2025cites this paper
• Opioid Control Policies Can Also Reduce Domestic Violence.

  2025cites this paper
• Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018

  2024cites this paper
• Comparing the effects of decreasing prescription opioid shipments and the release of an abuse deterrent OxyContin formulation on opioid overdose fatalities in WV: an interrupted time series study

  2024cites this paper
• Understanding the rise in overdose deaths involving opioids and non-opioid prescription drugs in the United States.

  2023cites this paper
• The Hazards of Unwinding the Prescription Opioid Epidemic: Implications for Child Maltreatment

  2022cites this paper
• Opioid epidemic: lessons learned and updated recommendations for misuse involving prescription versus non-prescription opioids

  2022cites this paper
• An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose

  2022cites this paper
• State-Level Prevalence and Associates of Opioid Dependence in the USA

  2022cites this paper
• Opioid Exposures Reported to U.S. Poison Centers

  2021cites this paper
• A Dual-Wall 3D-Printed Anti-tampering Medical Bottle

  2021cites this paper
• The release of abuse-deterrent OxyContin and adolescent heroin use.

  2021cites this paper
• Optimising Medicines Administration for Patients with Dysphagia in Hospital: Medical or Nursing Responsibility?

  2020cites this paper
• Retail Pharmacies and Drug Diversion during the Opioid Epidemic

  2020cites this paper
• Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective.

  2020cites this paper
• Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic

  2020cites this paper
• Probleme der Opioidanalgetika-Therapie aus psychiatrischer Sicht

  2019cites this paper
• How the Reformulation of OxyContin Ignited the Heroin Epidemic

  2019cites this paper
• Causal inference for evaluating prescription opioid abuse using trend‐in‐trend design

  2019cites this paper
• Controlled-release opioids cause harm and should be avoided in management of postoperative pain in opioid naïve patients.

  2019cites this paper
• How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?

  2019cites this paper
• The impact of the abuse-deterrent reformulation of extended-release OxyContin on prescription pain reliever misuse and heroin initiation.

  2019cites this paper
• Attenuating the Agent: Reducing Opioid “Virulence”

  2018cites this paper
• Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain

  2018cites this paper
• Management of Challenging Pharmacologic Issues in Chronic Pain and Substance Abuse Disorders.

  2018cites this paper
• Safety and performance of current abuse-deterrent formulations

  2018cites this paper
• Repeated blast model of mild traumatic brain injury alters oxycodone self‐administration and drug seeking

  2018cites this paper
• Public Policy: An Analgesia for Opioid Diversion

  2018cites this paper
• Impact of a chronic pain management pathway on opioid administration and prescribing in an Emergency Department

  2018cites this paper
• Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia

  2018cites this paper
• Abuse-deterrent opioids: an update on current approaches and considerations

  2018cites this paper
• Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties

  2018cites this paper
• Post‐marketing studies of pharmaceutical opioid abuse‐deterrent formulations: a framework for research design and reporting

  2018cites this paper
• Prescription opioid poisoning across urban and rural areas: identifying vulnerable groups and geographic areas

  2017cites this paper
• Endogenous Opiates and Behavior: 2015.

  2017cites this paper
• Patterns of Opioid Prescribing for an Orthopaedic Trauma Population

  2017cites this paper
• Relative preferences in the abuse of immediate‐release versus extended‐release opioids in a sample of treatment‐seeking opioid abusers

  2017cites this paper
• Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction‐Related Surveillance (RADARS) System Web Monitoring Program

  2017cites this paper
• Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration.

  2017cites this paper
• Abuse-deterrent Opioid Formulations

  2017cites this paper
• Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids.

  2016cites this paper
• The War on Drugs: Estimating the Effect of Prescription Drug Supply-Side Interventions

  2016cites this paper
• Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program

  2016cites this paper
• Prescription Opioid Policy and Illicit Drug Use

  2016influential citation
• Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).

  2016cites this paper
• Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.

  2016cites this paper
• Misuse and Abuse of Prescription Drugs

  2016cites this paper
• A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs

  2016cites this paper
• The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting

  2016cites this paper
• Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations

  2016cites this paper
• Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations

  2016cites this paper
• Emerging factors in the progression of cancer-related pain.

  2016cites this paper
• Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.

  2016cites this paper
• Drug Formulation Advances in Extended-Release Medications for Pain Control

  2016cites this paper
• Abuse-Deterrent Opioid Formulations.

  2015cites this paper
• Tamper-resistant drugs cannot solve the opioid crisis

  2015cites this paper
• Anticipated and unanticipated consequences of abuse deterrent formulations of opioid analgesics

  2015cites this paper
• Abuse-deterrent opioid formulations.

  2015cites this paper
• Commentary on Degenhardt et al (2015): a new formulation for research.

  2015cites this paper
• California Health Benefits Review Program Analysis of California Assembly Bill AB 623 Abuse-Deterrent Opioid Analgesics

  2015influential citation
• Abuse-Deterrent Formulations of Prescription Opioids.

  2015cites this paper
• Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.

  2015cites this paper
• The Risk of Opioid Intoxications or Related Events and the Effect of Alcohol-Related Disorders: A Retrospective Cohort Study in German Patients Treated with High-Potency Opioid Analgesics

  2015cites this paper
• Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.

  2015cites this paper
• Hydrocodone extended-release: pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy.

  2015cites this paper
• Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic

  2015cites this paper
• The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability

  2015cites this paper
• Clinicoeconomics and Outcomes Research Dovepress Estimating the Health Care Burden of Prescription Opioid Abuse in Five European Countries

  year unknowncites this paper
• Effect of auricular point bolus assisted OxyContin combined with alprazolam on psychology and quality of life in patients with malignant tumors

  year unknowncites this paper